

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

**CHANGE OF ADDRESS OF REGISTERED OFFICE,
HEADQUARTERS AND
PRINCIPAL PLACE OF BUSINESS IN THE PRC**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”) hereby announces that with effect from November 7, 2023, the address of the registered office, headquarters and principal place of business in the People’s Republic of China of the Company will be changed from 1st & 2nd Floors, Building 1, No. 18 Keji Avenue, Yuhang Street, Yuhang District, Hangzhou, Zhejiang, China to:

270 Shuyun Road, Cangqian Street, Yuhang District, Hangzhou, Zhejiang, China

All telephone and facsimile numbers of the Company will remain unchanged.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, November 7, 2023

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.